Sunday, September 20, 2026

FSSAI moves against Nestlé over baby formula claims and biotin test

Food regulator opens three cases over promotional claims on NAN Excella Pro and Lactogen Pro while a follow-up formula sample fails biotin tests; Nestlé says its products comply with regulations.

The Food Safety and Standards Authority of India (FSSAI) has initiated three separate cases against Nestlé India over alleged regulatory violations involving its infant nutrition products.

Two cases relate to promotional claims made for NAN Excella Pro Stage 1 and Lactogen Pro 1, while the third concerns a sample of Nestlé’s follow-up formula that the regulator found to have non-conforming levels of biotin.

The action follows the FSSAI’s examination of the products and promotional material available on e-commerce platforms. The regulator has raised concerns about claims made for the two infant formula products and about the nutritional composition of the follow-up formula sample.

What did FSSAI flag?

For NAN Excella Pro Stage 1, the FSSAI flagged claims relating to whey protein and five human milk oligosaccharides (HMOs), complex sugars naturally present in human breast milk. In the case of Lactogen Pro 1, the regulator raised concerns over a claim relating to whey protein, including its digestibility.

The FSSAI said such promotional claims are not permitted under India’s regulations governing foods for infant nutrition. The rules prohibit pictures, graphics or phrases intended to increase the saleability of infant milk substitutes or infant food. They also prohibit terms such as “Humanised” and “Maternalised”, as well as similar expressions.

The restrictions are part of a broader regulatory framework governing the marketing of infant milk substitutes in India.

The development has been welcomed by Dr Arun Gupta, chief coordinator of the Breastfeeding Promotion Network of India (BPNI) and one of the people involved in efforts surrounding the IMS Act. “This is a very encouraging development; they should pursue these cases,” Gupta said.

He said regulatory action was important because complaints relating to the promotion of infant formula had been made in the past, but did not always result in proceedings. “Nestlé certainly is one of the bigger producers of infant formula and this also sends a signal to the other companies to follow suit,” he said.

Why are infant formula advertisements so tightly regulated?

India has had restrictions on the promotion of infant milk substitutes for decades. The Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992, commonly known as the IMS Act, places restrictions on advertising and promotion of such products.

The law is intended to prevent marketing practices that could undermine breastfeeding or create the impression that infant milk substitutes are equivalent or superior to breast milk.

The FSSAI has cited both the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020 and the IMS Act in the action against Nestlé.

Separate concern over biotin

The third case concerns a follow-up formula; a product intended for older infants and children after the initial infant-formula stage. The FSSAI said a sample was found to be non-conforming with respect to its biotin content. Biotin, also known as vitamin B7, is a water-soluble vitamin involved in several metabolic processes.

The regulator said the sample was sent for re-analysis and that the referral laboratory also found it to be non-conforming. According to the applicable standards cited in the proceedings, infant food is required to contain 7.5 to 50 micrograms of biotin. The finding led to a separate case against Nestlé.

Nestlé says products comply with regulations

Nestlé India has said that its products comply with applicable regulations. The company has also indicated that the labels under scrutiny had been scientifically validated and approved by the FSSAI’s expert committee, and that it has submitted a detailed response to the regulator.

The company’s position is significant because the FSSAI proceedings are still at the regulatory stage. The initiation of a case does not by itself establish a final violation or mean that a penalty has already been imposed.

Why the scrutiny matters

Infant formula occupies a particularly sensitive area of food regulation because decisions about infant feeding have implications for both nutrition and breastfeeding practices. The latest action also comes amid increased scrutiny of infant nutrition products and their marketing. A 2024 investigation by Swiss NGO Public Eye reported differences in the sugar content of some Nestlé infant formula and baby-food products sold in lower-income countries, including India, compared with products sold in European markets.

Nestlé has previously maintained that its products comply with applicable Indian regulations and standards. The three cases initiated by the FSSAI will now go through the regulatory process. Their outcome will determine whether any violations are established and what action, if any, follows.

 

 

 

This is only for your information, kindly take the advice of your doctor for food, medicines, exercises and so on.   

 

 

Labels: , , ,

posted by G S Iyer at 10:33 AM 0 comments

Safer chemotherapy for penile cancer: Tata Memorial trial finds new treatment

A small randomised trial found fewer serious side effects and higher treatment-completion rates with paclitaxel than with a commonly used chemotherapy combination.

Chemotherapy uses medicines to kill cancer cells or stop them from growing and penile cancer needs early treatment lest it spreads to lymph nodes in the groin. 

A small clinical trial by doctors at Mumbai’s Tata Memorial Centre has found that a chemotherapy drug combination was easier for patients with high-risk penile cancer to tolerate than commonly used chemotherapy treatments.

Chemotherapy uses medicines to kill cancer cells or stop them from growing and penile cancer needs early treatment lest it spreads to lymph nodes in the groin.

The trial compared paclitaxel against 5-FU (fluorouracil), both of which were given with a platinum drug. Patients who received paclitaxel had fewer serious side effects, fewer treatment-related hospitalisations and were more likely to complete all four planned rounds of chemotherapy. However, the study was too small to establish whether paclitaxel was better at preventing the cancer from returning or helping patients live longer. The findings from the BACuP trial have been published in the Journal of the National Cancer Institute.

“Penile cancer is a rare cancer, and because of this, there is a lack of high-quality evidence to guide treatment,” said Dr Vanita Noronha, lead author of the paper and professor and medical oncologist at Tata Memorial Hospital, Mumbai. “There have not been any randomized studies evaluating chemotherapy regimens in penile cancer to date,” she said.

Why was the study needed?

Most earlier research on chemotherapy for penile cancer has looked back at patients who had already received different treatments. Doctors had not randomly assigned patients to different treatments, making such studies more vulnerable to bias.

“Treatment of patients was based on retrospective and observational studies which are low-quality evidence and prone to multiple biases,” Dr Noronha said. “Hence, we decided to attempt to conduct a randomised study to help understand the optimal chemotherapy regimen in men with penile cancer who had undergone surgery and were at high risk of the disease recurring,” she added.

What makes penile cancer high-risk?

Penile cancer is rare, accounting for less than one per cent of cancers in men worldwide. India reported 16,677 new cases in 2020, the highest number globally that year, according to the study. The cancer usually begins in the skin or lining of the penis and is most often a type called squamous cell cancer (happens in the outer layer of the skin). When found early, it can often be successfully treated with surgery.

The disease is considered particularly high-risk when the cancer has reached the pelvic lymph nodes, when it has grown outside a lymph node, or when a cancerous lymph node is at least 4 cm across. Chemotherapy given after surgery is intended to destroy cancer cells that may remain in the body but are too small to be seen on scans. This is known as adjuvant chemotherapy.

What drugs did patients receive?

The 49 men in the trial were randomly divided into two groups. One group received 5-FU plus a platinum drug. The other received paclitaxel plus a platinum drug.

While Paclitaxel interferes with the machinery cancer cells need to divide and multiply, 5-FU interferes with the way cells make and use DNA, which stops rapidly growing cancer cells from multiplying. The platinum drugs damage the DNA of cancer cells, making it difficult for them to grow and divide. Both groups were scheduled to receive four rounds of treatment, three weeks apart.

All participants were under 70 and had undergone surgery for penile cancer that had spread to lymph nodes and had at least one feature associated with a high risk of the cancer returning.

Paclitaxel caused fewer serious side effects

The biggest difference between the treatments was in their side effects. Serious treatment-related side effects occurred in 77.3 per cent of patients receiving 5-FU and a platinum drug, compared with 40.9 per cent of those receiving paclitaxel and a platinum drug.

Serious blood-related problems occurred in 54.5 per cent of patients in the 5-FU group, compared with 4.5 per cent in the paclitaxel group. Serious digestive problems, including vomiting and diarrhoea, occurred in 40.9 per cent of patients receiving 5-FU and a platinum drug, compared with 4.5 per cent receiving paclitaxel and a platinum drug.

Nearly half, 45.5 per cent, of patients in the 5-FU group had to be admitted to hospital because of treatment-related side effects. The figure was 9.1 per cent in the paclitaxel group.

Paclitaxel was also easier to administer. 5-FU usually has to be given continuously through a vein over several days, sometimes using a pump. Paclitaxel can generally be given as an intravenous infusion in a day-care or outpatient setting.

More patients completed treatment

About 83 per cent of patients receiving paclitaxel and a platinum drug completed all four planned rounds of treatment, compared with 48 per cent of those receiving 5-FU and a platinum drug. Patients in the 5-FU group also needed more medicines to increase their white blood cell counts and more reductions in their chemotherapy doses.

The researchers also looked at how long patients remained free of cancer and how long they survived. Patients receiving paclitaxel and a platinum drug remained free of cancer for a middle period of 19.6 months, compared with 12.4 months in the 5-FU group. The middle survival time was 36.7 months and 21.3 months, respectively.

But these figures cannot establish that paclitaxel improves survival. The study was small and was not designed to give a definite answer on which treatment controls the cancer better.

“The interpretation from the study should be that paclitaxel-platinum is safer and leads to fewer side-effects than 5FU-platinum; leads to fewer severe toxicities that require hospitalization for management, and higher treatment completion rates,” Dr Noronha said.

Earlier diagnosis remains important

Dr Noronha said the findings should encourage earlier recognition of penile cancer in India. Men with penile sores or other changes that do not go away, a tight foreskin, bleeding, discharge, or a wound or lump that does not heal should have an early medical examination rather than being repeatedly treated for a presumed infection, she said.

Cancer can spread to the groin lymph nodes even when they do not appear enlarged during an examination. “Nodal involvement is the strongest determinant of survival and delayed treatment is associated with substantially worse outcomes,” Dr Noronha said.

 

 

This is only for your information, kindly take the advice of your doctor for food, medicines, exercises and so on.   

 

 

 

 

Labels: , , ,

posted by G S Iyer at 10:27 AM 0 comments